Nasdaq Trda News Today

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]

- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving...

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total value of $160,132.14. Following the sale, the chief financial officer now owns 49,571 shares in the company, […]

Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.67, but opened at $15.90. Entrada Therapeutics shares last traded at $15.47, with a volume of 5,380 shares. Analyst Upgrades and Downgrades Separately, HC Wainwright reiterated a “buy” rating and […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $16.23, for a total transaction of $16,230.00. Following the completion of the sale, the chief executive officer now directly owns 246,279 […]

HC Wainwright reissued their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $25.00 price objective on the stock. Entrada Therapeutics Trading Up 3.5 % Shares of NASDAQ TRDA opened at $14.93 on Friday. The stock has […]

HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report report published on Friday, Benzinga reports. They currently have a $25.00 price target on the stock. Entrada Therapeutics Stock Performance Entrada Therapeutics stock opened at $14.42 on Friday. Entrada Therapeutics has a fifty-two week low of […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $15.00, for a total value of $15,000.00. Following the completion of the transaction, the chief executive officer now owns […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $15.00, for a total value of $15,000.00. Following the transaction, the chief executive officer now owns 248,279 shares of the […]